期刊文献+

雷洛昔芬对大鼠垂体瘤GH3细胞Seladin-1基因表达与增殖的影响 被引量:2

Effects of raloxifene on proliferation and seladin-1 gene expression in GH3 cells
原文传递
导出
摘要 目的探讨选择性雌激素受体拮抗剂雷洛昔芬对大鼠垂体瘤GH3细胞株的seladin-1基因表达及其对瘤细胞增殖的影响。方法以不同浓度(0.1~1 000 nmol/L)的雷洛昔芬作用于大鼠GH3细胞,培养48 h后检测雷洛昔芬的作用效果;荧光定量RT-PCR和Western blot分别检测seladin-1mRNA和蛋白;Cell Counting Kit-8试剂盒检测不同浓度药物对瘤细胞增殖的影响。结果雷洛昔芬在10~100 nmol/L的浓度范围能有效抑制selandin-1的表达,瘤细胞增殖受抑制(P<0.05)。结论雷洛昔芬能够有效抑制大鼠垂体瘤GH3细胞株selandin-1表达及瘤细胞生长,可作为垂体瘤的药物和基因治疗的新靶点。 Objective To explore the effects of raloxifene,a selective estrogen receptor antagonist,on proliferation and seladin-1 gene expression in rat GH-secreting(GH3)cells.Methods 48 h after raloxifene was added in a series of concentrations(0.1~1 000 nmol/L)to GH3 cells,the expression level of the seladin-1 gene was examined by quantitative real time RT-PCR and Western blot,and cell proliferation was investigated using the Cell Counting Kit-8.Results With quantitative real time RT-PCR and Western blot,it was found that,with the drug within the 10-100 nmol/L range,seladin-1 expression was significantly down-regulated and cell proliferation was inhibited in a concentration-dependent manner(P0.05).Conclusion Raloxifene suppresses seladin-1 expression and GH3 cell proliferation and,hence,it holds the promise of being used in treating pituitary adenoma.The seladin-1 gene may be a new target for gene therapy.
出处 《山东大学学报(医学版)》 CAS 北大核心 2012年第4期47-50,共4页 Journal of Shandong University:Health Sciences
基金 山东省科技攻关计划项目(2010GGB14010) 国家自然科学基金资助项目(81100836)
关键词 雷洛昔芬 seladin-1 GH3细胞 垂体瘤 Raloxifene Seladin-1 GH3 cells Pituitary adenoma
  • 相关文献

参考文献13

  • 1Luciani P,Gelmini S,Ferrante E. Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas[J].Journal of Clinical Endocrinology and Metabolism,2005,(11):6156-6161.
  • 2Elisa B. Statin-like drugs for the treatment of brain cholesterol loss in Alzheimer' s disease[J].Curr Drug Saf,2007,(03):173-176.
  • 3Luciani P,Deledda C,Rosati F. Seladin-1 is a fundamental mediator of neuroprotective effects of estrogen in human neuroblast long-term cell cultures[J].Endocrinology,2008,(09):4256-4266.doi:10.1210/en.2007-1795.
  • 4Di Stasi D,Vallacchi V,Campi V. DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis[J].International Journal of Cancer,2005,(02):224-230.doi:10.1002/ijc.20885.
  • 5Liu J K,Couldwell. Comtemporary management of prolactinomas[J].Neurosurgical Focus,2004,(04):E2.
  • 6Ciric I S,Zhao J. Transsphenoidal microsurgery:past,present and future[J].Expert Review of Anticancer Therapy,2006,(Suppl 9):s75-s78.
  • 7Wu C,Miloslavskaya I,Demontis S. Regulation of cellular response to oncogenic and oxidative stress by Seladin-1[J].Nature,2004,(7017):640-645.
  • 8Battista M C,Roberge C,Otis M. Seladin-1 expression in rat adrenal gland:effect of adrenocorticotropic hormone treatment[J].Journal of Endocrinology,2007,(01):53-66.
  • 9Benvenuti S,Luciani P,Vannelli G B. Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer' s disease indicator-1,a recently discovery antiapoptotic gene,in human neuroblast long-term cell cultures[J].J Clin Endocrinaol Metab,2005,(03):1775-1782.
  • 10Kansra S,Chen S,Bangaru M L. Selective estrogen receptor down-regulator and selective estrogen receptor modulators differentially regulate lactotroph proliferation[J].PLoS One,2010,(04):el0060.

二级参考文献10

  • 1WHI Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial [J]. JAMA, 2002, 288(3): 321-333.
  • 2Luck O, Maricic M. Raloxifene: recent information on skeletal and non-skeletal effects [J]. Curr Opin Rheumatol, 2002, 14(4): 429-432.
  • 3Nagykalnai T. Selective estrogen receptor modulators (SERMs) in the practice [J]. Magy Onkol, 2002, 46 (2): 165-175.
  • 4Figtree GA, Lu YQ, Webb CM, et al. Raloxifene acutely relaxs rabbit coronary arteries in vitro by an estrogen-dependent and nitric oxide-dependent mechanism [J]. Circulation, 1999, 100(10):1095-1101.
  • 5Watanabe T, Yoshizumi M, Akishita M, et al. Induction of nuclear orphan receptor NGFI-B gene and apoptosis in rat vascular smooth muscle cells treated with pyrrolidinedithiocarbamate [J]. Arterioscler Thromb Vasc Biol, 2001, 21(11):1738-1744.
  • 6Iijima K, Yoahizumi M, Ako J, et al. Expression of peroxisome proliferator-activated receptor gamma (PPAR gamma) in rat aortic smooth muscle cells [J].Bioche Biophys Res Commun, 1998, 247(2):353-356.
  • 7Altucci L, Addeo R, Cicatiello L, et al. 17beta-estradiol induces cyclin D1 gene transcription, p36D1p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells [J]. Oncogene, 1996;12 (11):2315-2324.
  • 8Dubey RK, Jackson EK, Gillespie DG, et al. Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity [J]. Arterioscler Thromb Vasc Biol 2000; 20(4):964-972.
  • 9Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors [J].Genes Dev, 2000, 14(2): 121-141.
  • 10Mckenna NJ, Lanz RB, O Malley BW. Nuclear receptor coregulators: cellular and molecular biology [J]. Endocr Rev, 1999, 20(3): 321-344.

共引文献1

同被引文献21

  • 1李广丽,刘晓春,林浩然.芳香化酶抑制剂letrozole对赤点石斑鱼(Epinephelus akaara)性逆转的作用[J].生理学报,2005,57(4):473-479. 被引量:25
  • 2Schlechte JA. Clinical practice. Prolactinoma [J]. N Engl Med, 2003, 349(21): 2035-2041.
  • 3Lloyd RV. Estrogen-induced hyperplasia and neoplasia in the mt anterior pituitary gland. An immunohistochemical study [J]. Am J Pathol, 2003, 113(2): 198-206.
  • 4Yamakawa K, Arita J. Cross-talk between the estrogen receptor-, protein kinase A-, and mitogen-activated protein kinase-mediated signaling pathways in the regulation of lactotroph proliferation in primary culture [J]. J Steroid Biochem Mol Biol, 2004, 88(2): 123-130.
  • 5Li C, Sun Z, Gui S, et al. Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism [J]. Neuro Endocrinol Lett, 2009, 30(2): 268-274.
  • 6Lopez JM, Oestreicher E. Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyper- prolactinemia resistant to dopamine agonists [J]. Fertil Steril, 2005, 84(3): 756.
  • 7Dadiboyena S. Recent advances in the synthesis of raloxi- fene: a selective estrogen receptor modulator [J]. Eur J Med Chem, 2012, 51: 17-34.
  • 8Wang H, Gorpudolo N, Behr B. The role of prolactin- and endometriosis-associated infertility [J]. Obstet Gynecol Surv, 2009, 64(8): 542-547.
  • 9Cosma M, Bailey J, Miles JM, et al. Pituitary and/or peri- pheral estrogen-receptor alpha regulates follicle- stimulat- ing hormone secretion, whereas central estrogenic path- ways direct growth hormone and prolactin secretion in postmenopausal women [J]. J Clin Endocrinol Metab, 2008, 93(3): 951-958.
  • 10Leung G, Tsao SW, Wong YC. The effect of flutamide and tamoxifen on sex hormone-induced mammary carcino- genesis and pituitary adenoma [J]. Breast Cancer Res Treat, 2002, 72(2): 153-162.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部